EssilorLuxottica SA Stock
Price
Target price
€268.40
€268.40
1.470%
3.9
1.470%
€290.00
15.08.25 / Tradegate
WKN: 863195 / Symbol: ESLOF / Name: EssilorLuxottica / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
EssilorLuxottica SA Stock
EssilorLuxottica SA gained 1.470% today.
The community is currently still undecided about EssilorLuxottica SA with 2 Buy predictions and 0 Sell predictions.
As a result the target price of 290 € shows a slightly positive potential of 8.05% compared to the current price of 268.4 € for EssilorLuxottica SA.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for EssilorLuxottica SA stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of EssilorLuxottica SA in the next few years
Pros
?
M***** P*******
?
S********** s********
?
B****
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of EssilorLuxottica SA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| EssilorLuxottica SA | 1.470% | 5.049% | 10.135% | 25.832% | 14.554% | 61.882% | 144.111% |
| bioMerieux S.A. | -1.100% | 0.880% | 5.171% | 28.346% | 22.546% | 21.134% | -8.623% |
| Sartorius Stedim Biotech S.A. | 0.450% | 6.186% | -9.616% | 3.526% | -3.320% | -54.178% | -37.754% |
| Teleflex Inc. | -0.970% | 2.000% | 4.615% | -50.962% | -39.286% | -58.871% | -67.925% |
Comments
News
EssilorLuxottica Stock: Smart Eyewear Drives Record Growth
EssilorLuxottica has posted impressive half-year results, with currency-adjusted revenue increasing by 7.3% to €14.02 billion, significantly exceeding analyst expectations. The standout performer
